[{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2||Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia||NF-?B\/NOS2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia||NF-?B\/NOS2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yaqrit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2","graph1":"Neurology","graph2":"Phase II","graph3":"Yaqrit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yaqrit \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yaqrit \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Amino Acid","year":"2013","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2","graph1":"Neurology","graph2":"Phase II","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"William Lee","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"IRELAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mallinckrodt Pharmaceuticals \/ William Lee","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ William Lee"}]

Find Clinical Drug Pipeline Developments & Deals for Ornithine Phenylacetate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : An ammonia scavenger, L-ornithine phenylacetate (OPA), is being evaluated for treatment of patients suffering from acute hepatic encephalopathy.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          February 11, 2025

                          Lead Product(s) : Ornithine Phenylacetate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : MNK-6105 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatic Encephalopathy.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          October 16, 2019

                          Lead Product(s) : Ornithine Phenylacetate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Ocera Therapeutics

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Ocera Therapeutics

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : OCR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          February 20, 2019

                          Lead Product(s) : Ornithine Phenylacetate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Ocera Therapeutics

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Ocera Therapeutics

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : Ornithine Phenylacetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatic Encephalopathy.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          October 21, 2013

                          Lead Product(s) : Ornithine Phenylacetate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Ocera Therapeutics

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Ocera Therapeutics

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : OCR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Liver Failure, Acute.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          July 06, 2012

                          Lead Product(s) : Ornithine Phenylacetate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : Ornithine Phenylacetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Failure, Acute.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          March 08, 2012

                          Lead Product(s) : Ornithine Phenylacetate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : William Lee

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank